Vertex Pharmaceuticals Incorporated (BIT:1VRTX)
Italy · Delayed Price · Currency is EUR | Market Cap | 117.03B +42.3% |
| Revenue (ttm) | 11.02B +10.2% |
| Net Income | 3.86B +21.1% |
| EPS | 15.04 +22.1% |
| Shares Out | n/a |
| PE Ratio | 30.35 |
| Forward PE | 30.93 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | n/a |
| Previous Close | 460.00 |
| Day's Range | n/a |
| 52-Week Range | 321.55 - 480.25 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 2, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
News
Vertex's Kidney Drug Success Sparks a 22% Surge for This Rival Biotech
Maze Therapeutics stock jumped after Vertex Pharmaceuticals reported positive results for inaxaplin, boosting confidence in a rival treatment from Maze.
Truist sees ‘significant positive readthrough’ for Maze from Vertex data
Truist analyst Danielle Brill views Vertex’s (VRTX) positive Phase 2 topline data as a meaningful validation of APOL1 inhibition in classic APOL1-mediated kidney disease and estimates the data support...
Vertex Pharmaceuticals announces positive results from Phase 2b inaxaplin study
The company states: “Vertex Pharmaceuticals (VRTX) announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease – AMKD – and modest proteinuri...
Vertex Announces Positive Results From Phase 2b AMPLIFIED Study of Inaxaplin in Additional Populations of People With APOL1-Mediated Kidney Disease (AMKD) and Completion of Enrollment in the Phase 2/3 AMPLITUDE Trial
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive results from the Phase 2b AMPLIFIED study of inaxaplin in people with APOL1-mediated kidney disease...
Vertex Pharmaceuticals partners with Lindsey Vonn for JOURNAVX awareness
Vertex Pharmaceuticals (VRTX) has partnered with world champion skier Lindsey Vonn to raise awareness of JOURNAVX, a prescription non-opioid medicine for the treatment of moderate-to-severe acute pain...
Vertex Pharmaceuticals Transcript: Morgan Stanley 24th Annual Global Healthcare Conference
The company is advancing a diversified pipeline with global launches in cystic fibrosis, expansion in renal and rare endocrine diseases, and promising assets in acute pain, diabetes, and genetic kidney disorders. Key near-term milestones include pivotal readouts for pove and inaxaplin, and continued rollout of ALYFTREK.
Strong Core Business, Raised Guidance Push Vertex Pharmaceuticals Higher
Since 2008, Vertex Pharmaceuticals, Inc. (VRTX) shares have received 42 outlier institutional inflow signals and gained over 1,682%.
Vertex Pharmaceuticals reinstated with an Overweight at JPMorgan
JPMorgan reinstated coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and price target of $560, up from $515, following a period of restriction. Vertex continues to expand with the…
Vertex Pharmaceuticals Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
The conference highlighted a diversified portfolio strategy, with recent acquisitions accelerating expansion into rare endocrine and renal diseases. Key near-term catalysts include regulatory milestones for povetacicept and inaxaplin, while commercial infrastructure has matured to support complex launches. PALSONIFY and atumelnant are positioned as major growth drivers.
Vertex Pharmaceuticals Transcript: Wells Fargo 21st Annual Healthcare Conference
Multiple near-term catalysts are expected, including pivotal renal data, a major IgAN launch, and key readouts in pain and rare diseases. Commercial strategies focus on clinical differentiation, patient access, and global expansion, with a vision for diversified revenue across five therapeutic pillars by 2027.
Vertex Pharmaceuticals resumed with an Overweight at Morgan Stanley
Morgan Stanley analyst Terence Flynn resumed coverage of Vertex Pharmaceuticals (VRTX) with an Overweight rating and $665 price target Progress of the company’s kidney pipeline is a key driver of…
Vertex Pharmaceuticals completes acquisition of Crinetics Pharmaceuticals
Vertex Pharmaceuticals (VRTX) announced the successful completion of the acquisition of Crinetics Pharmaceuticals (CRNX). Vertex also announced the expansion of its executive leadership team. Vertex e...
Vertex Completes Acquisition of Crinetics Pharmaceuticals and Announces Expansion of Executive Leadership Team
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the successful completion of the acquisition of Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pha...
Vertex Pharmaceuticals added to US Conviction List at Goldman Sachs
Goldman Sachs analysts added Vertex Pharmaceuticals (VRTX) to the firm’s US Conviction List as part of its monthly update. Goldman believes Vertex is well positioned for long-term growth as it…
Vertex to Participate in Upcoming September Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in four upcoming investor conferences. Susie Lisa, Senior Vice President of Investo...
Vertex Pharmaceuticals added to ‘US 1 List’ at BofA
BofA analysts added Vertex Pharmaceuticals (VRTX) to the firm’s “US 1 List.” The list represents BofA’s best investment ideas.
Vertex Pharmaceuticals price target raised to $672 from $605 at BofA
BofA raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $672 from $605 and keeps a Buy rating on the shares after competitor Sionna Therapeutics (SION) reported that its…
Vertex Stock (VRTX) Soars 7% as Rival Sionna (SION) Crashes 92% on Failed Drug Trial
Shares of American biotech company Vertex Pharmaceuticals ($VRTX) jumped about 7% on Monday after its top rival Sionna Therapeutics ($SION) reported the failure of a trial of its new cystic…
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
Vertex Pharmaceuticals price target raised to $565 from $560 at Truist
Truist raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $565 from $560 and keeps a Buy rating on the shares.
Vertex Pharmaceuticals price target raised to $617 from $615 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $617 from $615 and keeps an Overweight rating on the shares. The firm continues to like the share setup…
Vertex Pharmaceuticals price target raised to $605 from $600 at BofA
BofA analyst Tazeen Ahmad raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $605 from $600 and keeps a Buy rating on the shares. FY26 revenue guidance was raised…
Vertex Pharmaceuticals Earnings Call Transcript: Q2 2026
Q2 2026 revenue rose 12% year-over-year to $3.3B, led by CF, CASGEVY, and JOURNAVX growth. The company raised full-year guidance, advanced its pipeline, and announced the $8.8B Crinetics acquisition, adding a fifth commercial pillar in rare endocrine diseases.
Vertex Pharmaceuticals Earnings release: Q2 2026
Vertex Pharmaceuticals released its Q2 2026 earnings on August 3, 2026, summarizing the period's financial results.
Vertex Pharmaceuticals Slides: Q2 2026
Vertex Pharmaceuticals has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 3, 2026.